.png)
.png)
Latest news from BIA
BIA response to UK government’s plans for free trade deals and tariff plans
Steve Bates OBE, Chief Executive of the BioIndustry Association said: “For the UK life sciences sector to understand the benefit of any free trade deal we need to see the granular detail of what the UK hopes to achieve. Strengthening Intellectual Property regimes globally would benefit innovative UK life sciences businesses, so it is positive to see the Government recognises the importance of this issue in planning a US FTA.”
BIA welcomes publication of the Life Sciences 2030 Skills Strategy
The UK BioIndustry Association (BIA) has welcomed today’s publication of the Life Sciences 2030 Skills Strategy. The report is a key deliverable from the Life Sciences Sector Deal 2 and sets out how the UK Life Sciences sector will attract, retain, train and develop the research, manufacturing and technical skills required by a dynamic and diverse UK sector.
UK biotech records third highest year for investment despite global uncertainty
New figures published today (Wednesday 22 January 2020) by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveal that the UK biotech sector raised £1.3 billion in 2019. The total is the third highest year recorded by the trade association and since 2012 investment has increased by over 400%
BIA responds to the newly announced NHS England/Novartis deal
Commenting on the new NHS England/Novartis deal and the publication of the new UK life sciences sector update announced at JP Morgan today, Steve Bates OBE, Chief Executive of the BioIndustry Association said: "Global players are announcing the UK as their destination of choice for innovation at this year’s JP Morgan Healthcare conference.
Arecor Achieves Second License Milestone Payment from Global Pharmaceutical Partner
Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has achieved an important second, contractual milestone with one of its pharmaceutical partners. The first milestone was triggered in October 2017 following the signature of a license agreement between the parties.
Discovery Park potential recognised by Govt Life Sciences Opportunity Zone status
Discovery Park, the thriving science park for ambitious and growing life sciences companies, has been named a Life Sciences Opportunity Zone (LSOZ) by the UK Government’s Office for Life Sciences.
REVOLUTIONARY ADVANCES PROVIDED BY DIGITAL TWINS FOCUS OF EVENT AT DISCOVERY PARK
Sell-out ‘Two’s Company’ conference led by Pfizer UK, University of Kent, Kent, Surrey and Sussex AHSN
Enterprise Therapeutics appoints Dr David Morris MD as Chief Medical Officer
Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced it has appointed Dr David Morris MD as Chief Medical Officer to lead the Company’s respiratory programmes.
CEO Update|Monday 24 February
Over the weekend we have seen a rise in the number of cases of Coronavirus, particularly in Italy and South Korea, leading to more disruption to travel and closure of borders. We are now hearing that there have been disruptions to India’s pharmaceutical sector, India is a key player in the export of pharmaceuticals and relies on China for 70% of its raw ingredients. The BIA is continuing to work with innovative organisations across the UK to facilitate the development and scale-up of vaccines.
bioProcess UK poster presentation winner 2019
Posters have been an important factor of the annual bioProcessUK conference for the past few years. These sessions provide the opportunity for early career researchers to showcase their research, as well as themselves, in front of an audience including senior leaders across academic and industrial sectors of the UK bioprocessing community.
CEO Update|Monday 17 February
Boris Johnson has now confirmed his new Cabinet in a process which started with the surprise departure of Sajid Javid as Chancellor of the Exchequer.
Guest Blog | From open access science to open door laboratories
How unifying departments within academic institutions can increase research efficiency
Please find a selection of featured BIA publications below. To see our full publications library, click here.
Influencing and shaping our sector | BIA update: October 2019 - January 2020
This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences sector, from October 2019 to January 2020.
Global and growing - UK biotech financing in 2019
New figures published today (Wednesday 22 January 2020) by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveal that the UK biotech sector raised £1.3 billion in 2019.
UK life sciences: Catalysing investment and growth
This updated interim report sets out how the UK life sciences sector is driving investment and growth and makes the case for increased cost-effective public investment in the sector.
BIA biotech manifesto 2019
The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector.
